Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX) investors lost...
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX) investors lost...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.